Design and antitumor activity of immune checkpoint B7-H3 epitope vaccine
10.11665/j.issn.1000-5048.20210410
- VernacularTitle:免疫检查点B7-H3表位疫苗的设计及其抗肿瘤活性
- Author:
Xuefei XIA
;
Li ZHANG
;
Jianhua LUO
;
Wenbing YAO
;
Xiangdong GAO
;
Hong TIAN
- Publication Type:Journal Article
- Keywords:
immune checkpoint;
B7-H3;
epitope vaccine;
tumor immunity
- From:
Journal of China Pharmaceutical University
2021;52(4):472-479
- CountryChina
- Language:Chinese
-
Abstract:
B7-H3 is an immune checkpoint molecule overexpressed on the surface of a variety of tumors, and is is an ideal target for tumor immunotherapy. In this study, nitrolated T cell epitope designed in the early stage of the laboratory was used to construct an epitope vaccine that can target immune checkpoint B7-H3. The vaccine can significantly inhibit tumor growth in the CT26 colon cancer model, and has a significant synergistic effect with the PD-L1 protein vaccine. B7-H3 vaccine can increase the proportion of CD4+ T cells in splenic T lymphocytes and the proportion of CD8+ T cells in tumor-infiltrating T lymphocytes, while reducing the proportion of suppressor Treg cells in tumor-infiltrating CD4+ T lymphocytes, which effectively improves tumor immunosuppressive microenvironment. Research results suggest that the B7-H3 epitope vaccine can be used as an effective tumor vaccine candidate molecule.